Barclays
WX

Barclays’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Barclays’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-149,583
Closed -$6.43M – 7183
2015
Q3 		$6.43M Hold
149,583
– – 0.01% 1215
2015
Q2 		$6.28M Sell
149,583
-26,189
-15% -$1.1M 0.01% 1323
2015
Q1 		$6.68M Sell
175,772
-24,561
-12% -$946K 0.01% 1341
2014
Q4 		$6.61M Buy
200,333
+15,368
+8% +$543K 0.01% 1469
2014
Q3 		$6.47M Buy
184,965
+59
+0% +$2.02K 0.01% 1543
2014
Q2 		$5.92M Buy
184,906
+52,136
+39% +$1.78M 0.01% 1585
2014
Q1 		$4.78M Buy
132,770
+63,086
+91% +$2.32M 0.01% 1720
2013
Q4 		$2.65M Buy
69,684
+27,284
+64% +$861K ﹤0.01% 2385
2013
Q3 		$1.15M Buy
42,400
+26,800
+172% +$635K ﹤0.01% 3204
2013
Q2 		$328K Buy
+15,600
New +$305K ﹤0.01% 4701

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Barclays's WX Position: Q4 2015 in Review

Barclays sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 149,583 shares — an estimated $6.43M sold.

Barclays first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $6.68M in Q1 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Barclays reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Barclays sold 149,583 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $6.43M.
  • Barclays first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • Barclays's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $6.68M in Q1 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Barclays's 13F filing for Q4 2015, filed 12 Feb 2016.